Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Single Ascending-Dose Study to Characterize the Safety, Pharmacokinetics, and Pharmacodynamics of CEP-37251 in Healthy Postmenopausal Women

This study has been terminated.
(Study has been stopped by sponsor decision)
Sponsor:
Information provided by (Responsible Party):
Teva Pharmaceutical Industries ( Cephalon )
ClinicalTrials.gov Identifier:
NCT01159873
First received: July 8, 2010
Last updated: May 9, 2014
Last verified: May 2014
  Purpose

Study to Characterize the Safety, Pharmacokinetics, and Pharmacodynamics of CEP-37251 in Healthy Postmenopausal Women.


Condition Intervention Phase
Bone Loss
Osteoporosis
Drug: CEP-37251
Drug: Placebo
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled, Single Ascending-Dose Study to Characterize the Safety, Pharmacokinetics, and Pharmacodynamics of CEP-37251 in Healthy Postmenopausal Women

Resource links provided by NLM:


Further study details as provided by Teva Pharmaceutical Industries:

Primary Outcome Measures:
  • Characterize the Overall Safety Assessment of CEP-37251 [ Time Frame: 70 days ] [ Designated as safety issue: Yes ]
    Measurements include adverse events, laboratory results, vital sign measurements, electrocardiogram findings, physical examination findings, injection site evaluations, concomitant medication usage, immunophenotyping test results, and immunogenicity test results.


Secondary Outcome Measures:
  • Characterize the Overall Pharmacokinetic Profile of CEP-37251 [ Time Frame: 70 days ] [ Designated as safety issue: No ]
    Pharmacokinetic parameters include Cmax (Maximum Concentration) and AUC (Area Under the Curve) plasma concentration

  • Characterize the Overall Pharmacodynamic Effect of CEP-37251 [ Time Frame: 70 days ] [ Designated as safety issue: No ]
    Pharmacodynamic effect as measured by markers of bone metabolism


Enrollment: 2
Study Start Date: July 2010
Study Completion Date: October 2010
Primary Completion Date: October 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: CEP-37251 Drug: CEP-37251
up to 5 subcutaneous (sc) doses (given sequentially in cohort groups) of CEP-37251 (0.03, 0.1, 0.3, 1.0, and 3.0 mg/kg) will be studied. After all 5 sc doses have been studied, an intravenous (iv) dose of 0.3 mg/kg will be studied.
Placebo Comparator: Placebo Drug: Placebo
up to 5 subcutaneous (sc) doses (given sequentially in cohort groups) of Placebo (0.03, 0.1, 0.3, 1.0, and 3.0 mg/kg) will be studied. After all 5 sc doses have been studied, an intravenous (iv) placebo dose of 0.3 mg/kg will be studied.

  Eligibility

Ages Eligible for Study:   40 Years to 74 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • The subject is a postmenopausal woman aged 40 years or greater but less than 75 years.
  • The subject is ambulatory and healthy as judged by medical examination, medical history, and clinical chemistry, hematology and urinalysis at screening.
  • The subject has a body weight greater than 50 kg but no more than 100 kg with a body mass index (BMI) of 18 to 35 kg/m2).
  • The subject has a normal or clinically acceptable ECG.
  • The subject is willing to give written informed consent prior to any study-related procedures being conducted.
  • The subject is willing and able to comply with the study restrictions and to remain in the study center for the required inpatient period.

Exclusion Criteria:

  • The subject has received any of the following medications within the 6 months prior to enrollment:

    • hormone replacement therapy
    • selective estrogen receptor modulator (SERM) therapy such as raloxifene
    • elemental calcium supplementation >1.5 g/day
    • Vitamin D supplementation >1000 IU per day
    • calcitriol or other Vitamin D analogs (eg, alfacalcidol, doxercalciferol, or paricalcitol)
    • calcitonin or parathyroid hormone
    • chronic use of glucocorticoids NOTE: Acute use of glucocorticoids may be permitted after consultation with the medical monitor if it occurred a minimum of 6 weeks prior to enrollment
    • anabolic steroids
  • The subject has received bisphosphonates or fluoride within the 12 months prior to enrollment.
  • The subject has any of the following concomitant conditions:

    • hypo- or hyperthyroidism. NOTE: Subjects with treated hypothyroidism with normal thyroid parameters may be allowed to participate in the study at the discretion of the investigator and medical monitor.
    • hypo- or hyperparathyroidism
    • recent fracture (within 6 months)
    • osteomalacia, Paget's Disease, osteopetrosis, osteogenesis imperfect, or other bone disease
    • rheumatoid arthritis or psoriatic arthritis
    • acute osteoarthritis or gout
    • chronic kidney disease or renal failure defined as an eGFR (by MDRD equation) 30 mL/min/1.73 m2 or less
  • The subject is receiving immunosuppressant drugs.
  • The subject is currently participating in another investigational study or has received any investigational drug within 60 days before the dose of study drug.
  • The subject has evidence of severe, progressive, or uncontrolled renal, hepatic, hematologic, gastrointestinal, endocrine, pulmonary, cardiac, neurologic, psychiatric, or cerebral disease, or malabsorption syndrome.
  • The subject has a known history or evidence of malignancy, lymphoproliferative, or neoplastic disease with the exception of being successfully treated for basal or squamous cell carcinoma of the skin or cervical intraepithelial neoplasia.
  • The subject has had any substantial change in levels of physical activity or participated in intense physical activity (e.g., marathon training) within the 6 months prior to the dose of study drug.
  • The subject has any other clinically significant disease or disorder or factors, such as substance abuse, which in the opinion of the investigator, make the subject ineligible for participation in this study.
  • The subject has a known or suspected hypersensitivity or idiosyncratic reaction to any compound present in the study drug or placebo.
  • The subject has habitually consumed, within the past 2 years, more than 21 units of alcohol per week, or has a history of alcohol, narcotic, or any other substance abuse as defined by the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR). NOTE: A unit of alcohol is equal to approximately 30 ml of spirits, 100 ml of wine, or 260 ml of full-strength beer.
  • The subject has, within 2 weeks before administration of the dose of study drug, a clinically significant excessive consumption of coffee, tea, and/or other caffeine-containing beverage or food (i.e., 600 mg of caffeine or more per day, or 5 or more cups of coffee per day), or a combination of any of these beverages or foods.
  • The subject has had, within 4 weeks before the dose of study drug, a clinically significant illness or, within 1 week before the dose of study drug, has had any acute illness, or at screening or on the day before the dose of study drug, has symptoms of any clinically significant or acute illness.
  • The subject has, after resting for 5 minutes, elevated blood pressure (defined as a systolic blood pressure of more than 140 mm Hg for subjects ≤50 years of age or 155 mm Hg for subjects >50 years of age and/or a diastolic blood pressure of more than 90 mm Hg) or has low blood pressure (defined as systolic blood pressure of less than 90 mm Hg and/or diastolic blood pressure of less than 45 mm Hg).
  • The subject has, after resting for 5 minutes, a pulse less than 45 beats per minute (bpm). The subject has, after resting for 5 minutes, a pulse more than 90 bpm for subjects ≤50 years of age or a pulse more than 100 bpm for subjects >50 years of age.
  • The subject has a positive test result for hepatitis B surface antigen (HBsAg) or antibodies to hepatitis C or human immunodeficiency virus (HIV).
  • History of any clinically important drug and/or vaccine allergies.
  • The subject has received immunization with a live or live attenuated vaccine within 3 months prior to the dose of study drug or has immunization with a live or live attenuated vaccine planned within 3 months after the dose of study drug.
  • The subject has an ongoing active systemic infection requiring treatment or a history of severe infection, such as hepatitis or pneumonia, in the 3 months prior to the dose of study drug. Less severe infections in the 3 months prior to the dose of study drug are permitted at the discretion of the investigator and medical monitor.
  • The subject has a positive alcohol serum, urine, or breath test result or a positive urine drug screen (UDS).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01159873

Locations
Australia
Cephalon Investigational Site
Adelaide, Australia, 5000
Sponsors and Collaborators
Cephalon
Investigators
Study Director: Sr. Director, Clinical Pharmacology and Experimental Medicine, MD Cephalon
  More Information

No publications provided

Responsible Party: Teva Pharmaceutical Industries ( Cephalon )
ClinicalTrials.gov Identifier: NCT01159873     History of Changes
Other Study ID Numbers: C37251/1080
Study First Received: July 8, 2010
Last Updated: May 9, 2014
Health Authority: Australia: Department of Health and Ageing Therapeutic Goods Administration

Additional relevant MeSH terms:
Osteoporosis
Bone Diseases
Bone Diseases, Metabolic
Musculoskeletal Diseases

ClinicalTrials.gov processed this record on November 20, 2014